Proactis（PROAC）株式概要プロアクティスSAはソース・ツー・ペイのソフトウェア・ソリューションを提供している。 詳細PROAC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( €5M )French市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るPROAC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.03974.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-17m24m2016201920222025202620282031Revenue €11.9mEarnings €1.4mAdvancedSet Fair ValueView all narrativesProactis SA 競合他社VerimatrixSymbol: ENXTPA:VMXMarket cap: €15.7mLightOnSymbol: ENXTPA:ALTAIMarket cap: €23.3mWALLIX GROUPSymbol: ENXTPA:ALLIXMarket cap: €156.7mImmersionSymbol: ENXTPA:ALIMRMarket cap: €2.8m価格と性能株価の高値、安値、推移の概要Proactis過去の株価現在の株価€0.03952週高値€0.08952週安値€0.024ベータ01ヶ月の変化-11.36%3ヶ月変化-15.22%1年変化-36.07%3年間の変化-56.18%5年間の変化-75.00%IPOからの変化-99.76%最新ニュースお知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.最新情報をもっと見るRecent updatesお知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.分析記事 • Dec 05Proactis SA's (EPA:PROAC) Share Price Boosted 50% But Its Business Prospects Need A Lift TooProactis SA ( EPA:PROAC ) shares have had a really impressive month, gaining 50% after a shaky period beforehand. While...分析記事 • Oct 10Lacklustre Performance Is Driving Proactis SA's (EPA:PROAC) Low P/SYou may think that with a price-to-sales (or "P/S") ratio of 0.8x Proactis SA ( EPA:PROAC ) is a stock worth checking...お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.New Risk • Jul 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€8.33m market cap, or US$9.53m).お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 15% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Market cap is less than US$100m (€8.87m market cap, or US$10.2m).New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 15% over the past year. Market cap is less than US$10m (€8.13m market cap, or US$9.02m). Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Share price has been volatile over the past 3 months (9.7% average weekly change).New Risk • Feb 06New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€9.41m market cap, or US$9.76m).分析記事 • Jan 18Benign Growth For Proactis SA (EPA:PROAC) Underpins Its Share PriceProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.01m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.01m market cap, or US$9.85m).分析記事 • Oct 04The Market Doesn't Like What It Sees From Proactis SA's (EPA:PROAC) Revenues YetProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024分析記事 • May 24Estimating The Fair Value Of Proactis SA (EPA:PROAC)Key Insights The projected fair value for Proactis is €0.059 based on 2 Stage Free Cash Flow to Equity Current share...New Risk • Apr 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2023 fiscal period end). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue has declined by 12% over the past year. Minor Risk Market cap is less than US$100m (€9.75m market cap, or US$10.4m).Buy Or Sell Opportunity • Apr 11Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.043. The fair value is estimated to be €0.059, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Mar 26Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 45% to €0.045. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Mar 04Now 29% undervalued after recent price dropOver the last 90 days, the stock has fallen 46% to €0.041. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Feb 01Now 42% overvalued after recent price riseOver the last 90 days, the stock has risen 6.1% to €0.079. The fair value is estimated to be €0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.分析記事 • Jan 31A Look At The Intrinsic Value Of Proactis SA (EPA:PROAC)Key Insights Proactis' estimated fair value is €0.055 based on 2 Stage Free Cash Flow to Equity Current share price of...New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.13m (US$8.81m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (€8.13m market cap, or US$8.81m). Minor Risk Latest financial reports are more than 6 months old (reported January 2023 fiscal period end).New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.5m).お知らせ • May 23Proactis SA Announces Directorate ChangesProactis SA announced that under the terms of the general meeting of the company which took place on the 22 May 2023, Lucy FOX and Adrian MCSHANE-CHAPMAN have been appointed directors of PROACTIS SA, for a period of six (6) years. Lucy FOX joined the Proactis group as Chief Commercial Officer in January 2023 to improve the group's commercial growth. Adrian MCSHANE-CHAPMAN joined the Proactis group in April 2022 as Human Resources Manager in the United Kingdom, before being appointed Group People Services Lead. His mission is to make Proactis a career partner for employees by supporting them throughout their career within the company. In addition, Richard HUGHES and Rachel ROLLINSON have tendered their resignation from their role of directors of PROACTIS SA as of May 23, 2023. As a result of these changes, the Board of Directors of PROACTIS SA is made up of three members: Stephen LINE, Lucy FOX, and Adrian MCSHANE-CHAPMAN. The term of their mandate is expiring at the end of the shareholders meeting which will decide on the accounts for the 2028 financial year.Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.お知らせ • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023分析記事 • Dec 02Calculating The Intrinsic Value Of Proactis SA (EPA:PROAC)How far off is Proactis SA ( EPA:PROAC ) from its intrinsic value? Using the most recent financial data, we'll take a...Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 04Proactis (EPA:PROAC) Shareholders Will Want The ROCE Trajectory To ContinueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...分析記事 • Aug 09Estimating The Intrinsic Value Of Proactis SA (EPA:PROAC)Does the August share price for Proactis SA ( EPA:PROAC ) reflect what it's really worth? Today, we will estimate the...分析記事 • May 18Proactis (EPA:PROAC) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Feb 20We're Not Worried About Proactis' (EPA:PROAC) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.分析記事 • Oct 28Returns Are Gaining Momentum At Proactis (EPA:PROAC)There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...分析記事 • May 28There's Been No Shortage Of Growth Recently For Proactis' (EPA:PROAC) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term? One...分析記事 • Feb 12Will Proactis' (EPA:PROAC) Growth In ROCE Persist?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Reported Earnings • Dec 03Full year 2020 earnings released: €0.07 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: €12.4m (down 15% from FY 2019). Net loss: €9.77m (down €10.7m from profit in FY 2019).株主還元PROACFR SoftwareFR 市場7D5.4%2.0%-1.0%1Y-36.1%-40.0%-2.9%株主還元を見る業界別リターン: PROAC過去 1 年間で-40 % の収益を上げたFrench Software業界を上回りました。リターン対市場: PROACは、過去 1 年間で-2.9 % のリターンを上げたFrench市場を下回りました。価格変動Is PROAC's price volatile compared to industry and market?PROAC volatilityPROAC Average Weekly Movement36.8%Software Industry Average Movement6.9%Market Average Movement5.4%10% most volatile stocks in FR Market10.8%10% least volatile stocks in FR Market3.0%安定した株価: PROACの株価は、 French市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PROACの 週次ボラティリティ は、過去 1 年間で22%から37%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990n/aAndrew Reardonwww.proactis.comプロアクティスSAはソース・ツー・ペイのソフトウェア・ソリューションを提供している。ビジネス支出をコントロールするソフトウェア・プラットフォームを運営している。また、日常的な商品・サービス、資本財、主要プロジェクトの購買プロセスに必要なツールを購買担当者に提供する調達ソリューションも提供している。さらに、請求書の取り込みサービス、システム管理、サプライヤーのオンボーディング、支出管理サービスも提供している。さらに、同社のソリューションは様々なERPや財務システムと統合している。同社は以前はHUBWOOとして知られていたが、2019年1月にProactis SAに社名を変更した。同社はフランスのパリを拠点としている。Proactis SAはProactis Euro Hedgeco Limitedの子会社として運営されている。もっと見るProactis SA 基礎のまとめProactis の収益と売上を時価総額と比較するとどうか。PROAC 基礎統計学時価総額€5.28m収益（TTM）-€11.09m売上高(TTM)€11.93m0.0xP/Sレシオ0.0xPER（株価収益率PROAC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PROAC 損益計算書（TTM）収益€11.93m売上原価€10.52m売上総利益€1.41mその他の費用€12.50m収益-€11.09m直近の収益報告Jan 31, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%PROAC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 02:03終値2026/05/18 00:00収益2024/01/31年間収益2024/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Proactis SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).
Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).
New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).
お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
お知らせ • May 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 14April 2026, Mrs. Rebecca ARCHER has been appointed as Director in replacement of Mrs. Charlotte CARTER, resigning. Rebecca Archer joined Proactis in 2025. She is a Chartered Accountant and has a degree in Physics from the University of Oxford. She qualified at Deloitte where she spent six years including three years in New Zealand and has over 20 years of experience working in a variety of organizations including RM plc and Namene Solar. Rebecca was Group Finance Director at Science Group plc which was highly acquisitive where she led the business integrations and brings a wealth of business transformation experience to Proactis. During this same meeting, Mr. Phil DENNANT has been appointed as Director in replacement of Mr. Peter SHEPHERD, resigning. Mr. Philip Dennant joined Proactis in 2021. He currently holds the position of Director of FP&A, responsible for financial planning and strategic analysis to support executive decision-making and long-term business growth. Prior to this, he spent nearly a decade working within large UK-listed companies. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON serves as Chairman of the Board of Directors and Chief Executive Officer, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Rebecca ARCHER holds the position of Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Phil DENNANT is also a Director, with his mandate expiring at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN serves as Director, and her mandate will expire at the Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
New Risk • Apr 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2024 fiscal period end). Share price has been highly volatile over the past 3 months (36% average weekly change). Market cap is less than US$10m (€5.42m market cap, or US$6.34m).
Buy Or Sell Opportunity • Apr 21Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.1% to €0.043. The fair value is estimated to be €0.055, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
New Risk • Apr 19New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Market cap is less than US$10m (€5.96m market cap, or US$7.01m).
New Risk • Feb 01New major risk - Revenue and earnings growthRevenue has declined by 22% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue has declined by 22% over the past year. Market cap is less than US$10m (€6.57m market cap, or US$7.79m). Minor Risk Negative equity (-€947k).
お知らせ • Dec 19Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning. Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan. During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning. Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution. Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31, 2026. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON: Chairman of the Board of Directors, Chief Executive Officer: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Charlotte CARTER: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Peter SHEPHERD: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN: Director: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
分析記事 • Dec 05Proactis SA's (EPA:PROAC) Share Price Boosted 50% But Its Business Prospects Need A Lift TooProactis SA ( EPA:PROAC ) shares have had a really impressive month, gaining 50% after a shaky period beforehand. While...
分析記事 • Oct 10Lacklustre Performance Is Driving Proactis SA's (EPA:PROAC) Low P/SYou may think that with a price-to-sales (or "P/S") ratio of 0.8x Proactis SA ( EPA:PROAC ) is a stock worth checking...
お知らせ • Oct 08Proactis SA to Report Fiscal Year 2025 Results on Oct 08, 2025Proactis SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Oct 08, 2025
お知らせ • Sep 04Proactis SA Announces Board ChangesUnder the terms of the Board of Directors of the company PROACTIS SA held on the 31st of August 2025, Mrs. Maria LARSEN was co-opted as a director to replace Mrs. Lucy FOX, who resigned. Shareholders will be asked to approve this appointment at the next Annual General Meeting called to approve the financial statements. Maria LARSEN joined the PROACTIS Group in April 2025 as Customer Success and Transformation Director. Maria's diverse career spans leadership roles within the British Army, humanitarian aid and transformational management consultancy. She brings exceptional leadership experience and a deep passion for stakeholder engagement. Maria LARSEN has delivered high-impact solutions for the private sector, third sector, the MoD, DHSC, and other public sector organizations. As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows: Andrew REARDON,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028, Bonnie MITCHELL: Director: Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2030. Graham DAVIS:Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028. Maria LARSEN,Mandatory expiry date: Annual General Meeting to approve the financial statements for the year ending January 31, 2028.
New Risk • Jul 31New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€8.33m market cap, or US$9.53m).
お知らせ • Jul 02Proactis SA Approves Resignation of Monsieur Adrian MCSHANE-CHAPMAN as DirectorUnder the terms of the Board of Directors of the company PROACTIS SA held on the 25 June, Mr. Monsieur Adrian MCSHANE-CHAPMAN, resigning.
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue has declined by 15% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Market cap is less than US$100m (€8.87m market cap, or US$10.2m).
New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 15% over the past year. Market cap is less than US$10m (€8.13m market cap, or US$9.02m). Minor Risks Latest financial reports are more than 6 months old (reported January 2024 fiscal period end). Share price has been volatile over the past 3 months (9.7% average weekly change).
New Risk • Feb 06New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€9.41m market cap, or US$9.76m).
分析記事 • Jan 18Benign Growth For Proactis SA (EPA:PROAC) Underpins Its Share PriceProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...
New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.01m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.01m market cap, or US$9.85m).
分析記事 • Oct 04The Market Doesn't Like What It Sees From Proactis SA's (EPA:PROAC) Revenues YetProactis SA's ( EPA:PROAC ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now compared to...
お知らせ • Sep 27Proactis SA to Report Fiscal Year 2024 Results on Sep 26, 2024Proactis SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Sep 26, 2024
分析記事 • May 24Estimating The Fair Value Of Proactis SA (EPA:PROAC)Key Insights The projected fair value for Proactis is €0.059 based on 2 Stage Free Cash Flow to Equity Current share...
New Risk • Apr 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended January 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported January 2023 fiscal period end). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue has declined by 12% over the past year. Minor Risk Market cap is less than US$100m (€9.75m market cap, or US$10.4m).
Buy Or Sell Opportunity • Apr 11Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.043. The fair value is estimated to be €0.059, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Mar 26Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 45% to €0.045. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Mar 04Now 29% undervalued after recent price dropOver the last 90 days, the stock has fallen 46% to €0.041. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Feb 01Now 42% overvalued after recent price riseOver the last 90 days, the stock has risen 6.1% to €0.079. The fair value is estimated to be €0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last year. Meanwhile, the company became loss making.
分析記事 • Jan 31A Look At The Intrinsic Value Of Proactis SA (EPA:PROAC)Key Insights Proactis' estimated fair value is €0.055 based on 2 Stage Free Cash Flow to Equity Current share price of...
New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.13m (US$8.81m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 11% per year over the past 5 years. Market cap is less than US$10m (€8.13m market cap, or US$8.81m). Minor Risk Latest financial reports are more than 6 months old (reported January 2023 fiscal period end).
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Market cap is less than US$100m (€11.5m market cap, or US$12.5m).
お知らせ • May 23Proactis SA Announces Directorate ChangesProactis SA announced that under the terms of the general meeting of the company which took place on the 22 May 2023, Lucy FOX and Adrian MCSHANE-CHAPMAN have been appointed directors of PROACTIS SA, for a period of six (6) years. Lucy FOX joined the Proactis group as Chief Commercial Officer in January 2023 to improve the group's commercial growth. Adrian MCSHANE-CHAPMAN joined the Proactis group in April 2022 as Human Resources Manager in the United Kingdom, before being appointed Group People Services Lead. His mission is to make Proactis a career partner for employees by supporting them throughout their career within the company. In addition, Richard HUGHES and Rachel ROLLINSON have tendered their resignation from their role of directors of PROACTIS SA as of May 23, 2023. As a result of these changes, the Board of Directors of PROACTIS SA is made up of three members: Stephen LINE, Lucy FOX, and Adrian MCSHANE-CHAPMAN. The term of their mandate is expiring at the end of the shareholders meeting which will decide on the accounts for the 2028 financial year.
Reported Earnings • Jan 15Full year 2022 earnings releasedFull year 2022 results: Revenue: €14.4m (up 28% from FY 2021). Net income: €290.0k (up €816.0k from FY 2021). Profit margin: 2.0% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.
お知らせ • Jan 12+ 1 more updateProactis SA to Report Fiscal Year 2022 Results on Jan 12, 2023Proactis SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Jan 12, 2023
分析記事 • Dec 02Calculating The Intrinsic Value Of Proactis SA (EPA:PROAC)How far off is Proactis SA ( EPA:PROAC ) from its intrinsic value? Using the most recent financial data, we'll take a...
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 04Proactis (EPA:PROAC) Shareholders Will Want The ROCE Trajectory To ContinueTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
分析記事 • Aug 09Estimating The Intrinsic Value Of Proactis SA (EPA:PROAC)Does the August share price for Proactis SA ( EPA:PROAC ) reflect what it's really worth? Today, we will estimate the...
分析記事 • May 18Proactis (EPA:PROAC) Is Looking To Continue Growing Its Returns On CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • May 02First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €659.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021).
Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CFO & Director Richard Hughes was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Feb 20We're Not Worried About Proactis' (EPA:PROAC) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Dec 03Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €11.2m (down 9.7% from FY 2020). Net loss: €526.0k (loss narrowed 95% from FY 2020). Revenue was in line with analyst estimates.
分析記事 • Oct 28Returns Are Gaining Momentum At Proactis (EPA:PROAC)There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
分析記事 • May 28There's Been No Shortage Of Growth Recently For Proactis' (EPA:PROAC) Returns On CapitalWhat are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
分析記事 • Feb 12Will Proactis' (EPA:PROAC) Growth In ROCE Persist?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Reported Earnings • Dec 03Full year 2020 earnings released: €0.07 loss per shareThe company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: €12.4m (down 15% from FY 2019). Net loss: €9.77m (down €10.7m from profit in FY 2019).
